Harmony Biosciences stock falls after Phase 3 trial misses endpoint
NegativeFinancial Markets

Harmony Biosciences faced a setback as its stock price dropped following the announcement that its Phase 3 trial did not meet its primary endpoint. This news is significant as it raises concerns about the company's future prospects and the effectiveness of its treatments, potentially impacting investor confidence and market performance.
— Curated by the World Pulse Now AI Editorial System